Kura Oncology Reports Third Quarter 2023 Financial Results
02. November 2023 16:01 ET
|
Kura Oncology, Inc.
– Completion of enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML expected by mid-2024 – – Preliminary data from 20 patients in KOMET-007 combination trial of...
Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
09. Februar 2023 07:30 ET
|
Kura Oncology, Inc.
– Phase 1 trial showed 30% CR rate among 20 NPM1-mutant AML patients treated at recommended Phase 2 dose – – Phase 2 registration-directed trial expected to enroll 85 patients in the U.S. and Europe...
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting
10. Dezember 2022 10:30 ET
|
Kura Oncology, Inc.
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant patients treated...
Kura Oncology to Host Investor Event on December 10, 2022
01. Dezember 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting
03. November 2022 09:00 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Third Quarter 2022 Financial Results
03. November 2022 07:30 ET
|
Kura Oncology, Inc.
– Abstract reporting updated data from KOMET-001 accepted for oral presentation at ASH – – First demonstration of durable clinical response with tipifarnib plus alpelisib in HNSCC – – AIM-HN...
Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million
03. November 2022 07:00 ET
|
Kura Oncology, Inc.
– $25 million equity investment from Bristol Myers Squibb at $18.25 per share – – Term loan facility from Hercules Capital provides up to $125 million – – Proceeds extend Kura’s cash runway into...
Kura Oncology Reports Second Quarter 2022 Financial Results
03. August 2022 16:03 ET
|
Kura Oncology, Inc.
– Recommended Phase 2 dose for ziftomenib identified, pending FDA review – – Additional 18 patients enrolled in KOMET-001 trial of ziftomenib in NPM1-mutant and KMT2A-rearranged AML – ...
Kura Oncology Reports First Quarter 2022 Financial Results
04. Mai 2022 16:05 ET
|
Kura Oncology, Inc.
– Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter – – Enrollment in PIK3CA-dependent cohort in...
Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results
24. Februar 2022 16:03 ET
|
Kura Oncology, Inc.
– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML – – Multiple milestones and data readouts from KOMET-001 expected in 2022 – – First patients dosed in Phase...